Everything you care about in one place

Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.

Get Feeder
← Find more feeds

ir.clovisoncology.com

Clovis Oncology, Inc. Press Releases

Get the latest updates from Clovis Oncology, Inc. Press Releases directly as they happen.

Follow now 74 followers

Latest posts

Last updated over 2 years ago

Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

over 2 years ago

Clovis Oncology Presents Data from TRITON3 Phase 3 Trial of Rubraca® (rucaparib) at the 29th Annual Prostate Cancer Foundation Scientific Retreat

over 2 years ago

Clovis Oncology Highlights Updated LuMIERE Phase 1 Data of Targeted Radiotherapy Candidate FAP-2286 at the 35th Annual EANM Congress

over 2 years ago

TRITON3 Phase 3 Trial of Rubraca® (rucaparib) Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

over 2 years ago

Clovis Oncology and Isotopia Announce Lutetium-177 Clinical Supply Agreement

over 2 years ago

Clovis Oncology Submits Applications for Rubraca® Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer

over 2 years ago

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Improves Progression-Free Survival in Women with Advanced Ovarian Cancer Across Disease Risk Subgroups

over 2 years ago

Clovis Oncology Announces Second Quarter 2022 Operating Results and Provides Update on Clinical Development Programs

almost 3 years ago

CORRECTING and REPLACING Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

almost 3 years ago

Clovis Oncology to Announce Second Quarter 2022 Financial Results and Host Webcast Conference Call on August 8

almost 3 years ago

Clovis Oncology Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

almost 3 years ago

Clovis Oncology’s Rubraca® (Rucaparib) as First-Line Maintenance Treatment Significantly Improves Progression-Free Survival in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD Status

almost 3 years ago

Sign up to continue

Try Feeder for free

Everything you care about in one place

Try Feeder now